Latest Novo Nordisk News & Updates
See the latest news and media coverage for Novo Nordisk. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global healthcare company focused on diabetes and obesity
novonordisk.com- Headquarters
- Bagsværd, Denmark
- Founded year
- 1923
- Company type
- Public company
- Number of employees
- 60,000+
Last updated
Latest news about Novo Nordisk
In short: Novo Nordisk raised its 2026 financial guidance following strong sales growth and the successful U.S. launch of its oral weight-loss medication.
Company announcements
-
Novo Nordisk reports Q1 2026 financial results
Adjusted operating profit reaches DKK 32,858 million. Sales grow 32% at CER due to 340B reversal; adjusted sales decline 4%. Raises 2026 outlook. Wegovy pill launches strongly.
-
Novo Nordisk ranks among TIME's 100 Most Influential Companies 2026
The recognition honors their disruption in obesity treatment and GLP-1 science for patients worldwide.
-
Novo Nordisk publishes phase 3 data on denecimig
Data shows significantly reduced annualized bleeding rate in haemophilia A patients, regardless of inhibitor status, versus prior prophylaxis or on-demand treatment.
-
Novo Nordisk presents new Wegovy data at Obesity Congress
Data covers higher-dose Wegovy, oral semaglutide, and CagriSema, focusing on weight loss, menopausal symptoms, and cardiovascular risk.
Media coverage
-
Novo Nordisk India Sales Jump 40% As Generic Pressure Builds
This article first appeared on GuruFocus. Novo Nordisk A/S (NYSE:NVO) may have just delivered an early warning shot in India's fast-moving obesity-drug market. Instead of...
-
Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand...
-
Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk
New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.
-
Medicare to start offering weight loss drugs for $50 per month
The Medicare GLP-1 Bridge program will run between July 1, 2026, and Dec. 31, 2027. Novo Nordisk -...
Track Novo Nordisk and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore